Chagas disease immunogenetics: elusive markers of disease progression

References

• Sabino EC, Ribeiro AL, Salemi VM, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation. 2013;127(10):1105–1115.
   PubMed Web of Science ®Google Scholar
• Zicker F, Smith PG, Netto JC, et al. Physical activity, opportunity for reinfection, and sibling history of heart disease as risk factors for Chagas’ cardiopathy. Am J Trop Med Hyg. 1990;43(5):498–505.
   PubMed Web of Science ®Google Scholar
• Soares MB, Pontes-De-Carvalho L, Ribeiro-Dos-Santos R. The pathogenesis of Chagas’ disease: when autoimmune and parasite-specific immune responses meet. An Acad Bras Cienc. 2001;73(4):547–559.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373(14):1295–1306.
   PubMed Web of Science ®Google Scholar
• Teixeira AR, Hecht MM, Guimaro MC, et al. Pathogenesis of chagas’ disease: parasite persistence and autoimmunity. Clin Microbiol Rev. 2011;24(3):592–630.
   PubMed Web of Science ®Google Scholar
• De Oliveira AP, Ayo CM, Bestetti RB, et al. The role of CCR5 in Chagas disease - a systematic review. Infect Genet Evol. 2016;45:132–137.
   PubMed Web of Science ®Google Scholar
• Luz PR, Miyazaki MI, Neto NC, et al. High levels of mannose-binding lectin are associated with the risk of severe cardiomyopathy in chronic Chagas disease. Int J Cardiol. 2010;143(3):448–450.
   PubMed Web of Science ®Google Scholar
• Luz PR, Boldt AB, Grisbach C, et al. Association of L-ficolin levels and FCN2 genotypes with chronic Chagas disease. PLoS One. 2013;8(4):e60237.
   PubMed Web of Science ®Google Scholar
• Bafica A, Santiago HC, Goldszmid R, et al. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol. 2006;177(6):3515–3519.
   PubMed Web of Science ®Google Scholar
• Silva GK, Costa RS, Silveira TN, et al. Apoptosis-associated speck-like protein containing a caspase recruitment domain inflammasomes mediate IL-1beta response and host resistance to Trypanosoma cruzi infection. J Immunol. 2013;191(6):3373–3383.
   PubMed Web of Science ®Google Scholar
• Dey N, Sinha M, Gupta S, et al. Caspase-1/ASC inflammasome-mediated activation of IL-1beta-ROS-NF-kappaB pathway for control of Trypanosoma cruzi replication and survival is dispensable in NLRP3-/- macrophages. PLoS One. 2014;9(11):e111539.
   PubMed Web of Science ®Google Scholar
• Cruz Gda S, Angelo AL, Larocca TF, et al. Assessment of galectin-3 polymorphism in subjects with chronic Chagas disease. Arq Bras Cardiol. 2015;105(5):472–478.
   PubMed Web of Science ®Google Scholar
• Junqueira C, Caetano B, Bartholomeu DC, et al. The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med. 2010;12:e29.
   PubMed Web of Science ®Google Scholar
• Hudson L. Trypanosoma cruzi: the immunological consequences of infection. J Cell Biochem. 1983;21(4):299–304.
   PubMed Web of Science ®Google Scholar
• Hudson L, Guhl F, De Sanchez N, et al. Longitudinal studies of the immune response of Colombian patients infected with Trypanosoma cruzi and T. rangeli. Parasitology. 1988;96(Pt 3):449–460.
   PubMed Web of Science ®Google Scholar
• Ribeirão M, Pereira-Chioccola VL, Rénia L, et al. Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase. Parasite Immunol. 2000;22(1):49–53.
   PubMed Web of Science ®Google Scholar
• Trouiller P, Rey JL, Bouscharain P. [Pharmaceutical development concerning diseases predominating in tropical regions: the concept of indigent drugs]. Ann Pharm Fr. 2000;58(1):43–46.
   PubMedGoogle Scholar
• Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis. 2012;54(6):845–852.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC, et al. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115(9):1109–1123.
   PubMed Web of Science ®Google Scholar
• Beltz LA, Sztein MB, Kierszenbaum F. Novel mechanism for Trypanosoma cruzi-induced suppression of human lymphocytes. Inhibition of IL-2 receptor expression. J Immunol. 1988;141(1):289–294.
   Google Scholar
• Cetron MS, Basilio FP, Moraes AP, et al. Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas’ disease patients with symptomatic versus indeterminate infection. Am J Trop Med Hyg. 1993;49(3):370–382.
   PubMed Web of Science ®Google Scholar
• Gil-Jaramillo N, Motta FN, Favali CB, et al. Dendritic cells: a double-edged sword in immune responses during Chagas disease. Front Microbiol. 2016;7:1076.
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Chevillard C. Chagas disease cardiomyopathy: immunopathology and genetics. Mediators Inflamm. 2014;2014:683230.
   PubMed Web of Science ®Google Scholar
• Ayo CM, Dalalio MMDO, Visentainer JE, et al. Genetic susceptibility to Chagas disease: an overview about the infection and about the association between disease and the immune response genes. Biomed Res Int. 2013;2013:1–13.
   Web of Science ®Google Scholar
• Del Puerto F, Nishizawa JE, Kikuchi M, et al. Protective human leucocyte antigen haplotype, HLA-DRB1*01-B*14, against chronic Chagas disease in Bolivia. PLoS Negl Trop Dis. 2012;6(3):e1587.
   PubMed Web of Science ®Google Scholar
• Dias FC, Castelli EC, Collares CV, et al. The role of HLA-G molecule and HLA-G gene polymorphisms in tumors, viral hepatitis, and parasitic diseases. Front Immunol. 2015;6:9.
   PubMed Web of Science ®Google Scholar
• Corbett CE, Ribeiro U Jr., Prianti MG, et al. Cell-mediated immune response in megacolon from patients with chronic Chagas’ disease. Dis Colon Rectum. 2001;44(7):993–998.
   PubMed Web of Science ®Google Scholar
• El-Sayed NM, Myler PJ, Bartholomeu DC, et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science. 2005;309(5733):409–415.
   PubMed Web of Science ®Google Scholar
• Atwood JA 3rd, Weatherly DB, Minning TA, et al. The Trypanosoma cruzi proteome. Science. 2005;309(5733):473–476.
   PubMed Web of Science ®Google Scholar
• Martin DL, Weatherly DB, Laucella SA, et al. CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog. 2006;2(8):e77.
   PubMed Web of Science ®Google Scholar
• Alvarez MG, Postan M, Weatherly DB, et al. HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis. 2008;2(9):e288.
   PubMed Web of Science ®Google Scholar
• Dauby N, Alonso-Vega C, Suarez E, et al. Maternal infection with Trypanosoma cruzi and congenital Chagas disease induce a trend to a type 1 polarization of infant immune responses to vaccines. PLoS Negl Trop Dis. 2009;3(12):e571.
   PubMed Web of Science ®Google Scholar
• Olivera GC, Albareda MC, Alvarez MG, et al. Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect. 2010;12(5):359–363.
   PubMed Web of Science ®Google Scholar
• Tonelli RR, Torrecilhas AC, Jacysyn JF, et al. In vivo infection by Trypanosoma cruzi: the conserved FLY domain of the gp85/trans-sialidase family potentiates host infection. Parasitology. 2011;138(4):481–492.
   PubMed Web of Science ®Google Scholar
• Kierszenbaum F, Lopez HM, Sztein MB. Inhibition of Trypanosoma cruzi-specific immune responses by a protein produced by T. cruzi in the course of Chagas’ disease. Immunology. 1994;81(3):462–467.
   PubMed Web of Science ®Google Scholar
• Zhang S, Kim CC, Batra S, et al. Delineation of diverse macrophage activation programs in response to intracellular parasites and cytokines. PLoS Negl Trop Dis. 2010;4(3):e648.
   PubMed Web of Science ®Google Scholar
• Gomes JA, Bahia-Oliveira LM, Rocha MO, et al. Evidence that development of severe cardiomyopathy in human Chagas’ disease is due to a Th1-specific immune response. Infect Immun. 2003;71(3):1185–1193.
   PubMed Web of Science ®Google Scholar
• Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Semin Immunopathol. 2015;37(3):233–238.
   PubMed Web of Science ®Google Scholar
• Gutierrez FR, Guedes PM, Gazzinelli RT, et al. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol. 2009;31(11):673–685.
   PubMed Web of Science ®Google Scholar
• Sullivan NL, Eickhoff CS, Sagartz J, et al. Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion. J Immunol. 2015;194(4):1806–1818.
   PubMed Web of Science ®Google Scholar
• Gutierrez FR, Mariano FS, Oliveira CJ, et al. Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1. Infect Immun. 2011;79(5):1873–1881.
   PubMed Web of Science ®Google Scholar
• Dutra WO, Martins-Filho OA, Cancado JR, et al. Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Scand J Immunol. 1996;43(1):88–93.
   PubMed Web of Science ®Google Scholar
• Souza PE, Rocha MO, Menezes CA, et al. Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas’ disease. Infect Immun. 2007;75(4):1886–1894.
   PubMed Web of Science ®Google Scholar
• De Araujo FF, Da Silveira AB, Correa-Oliveira R, et al. Characterization of the presence of Foxp3(+) T cells from patients with different clinical forms of Chagas’ disease. Hum Pathol. 2011;42(2):299–301.
   PubMed Web of Science ®Google Scholar
• Bonney KM, Engman DM. Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead. Am J Pathol. 2015;185(6):1537–1547.
   PubMed Web of Science ®Google Scholar
• Michailowsky V, Luhrs K, Rocha MO, et al. Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas’ disease. Infect Immun. 2003;71(6):3165–3171.
   PubMed Web of Science ®Google Scholar
• Duschak VG, Riarte A, Segura EL, et al. Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas disease. Immunol Lett. 2001;78(3):135–142.
   PubMed Web of Science ®Google Scholar
• Kierszenbaum F. On evasion of Trypanosoma cruzi from the host immune response. Lymphoproliferative responses to trypanosomal antigens during acute and chronic experimental Chagas’ disease. Immunology. 1981;44(3):641–648.
   PubMed Web of Science ®Google Scholar
• DosReis GA. Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz J Med Biol Res = Revista Brasileira De Pesquisas Medicas E Biologicas. 2011;44(2):84–90.
   PubMed Web of Science ®Google Scholar
• Nogueira LG, Santos RH, Ianni BM, et al. Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10. PLoS Negl Trop Dis. 2012;6(10):e1867.
   PubMed Web of Science ®Google Scholar
• Machado FS, Koyama NS, Carregaro V, et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis. 2005;191(4):627–636.
   PubMed Web of Science ®Google Scholar
• De Oliveira AP, Bernardo CR, Camargo AV, et al. Genetic susceptibility to cardiac and digestive clinical forms of chronic Chagas disease: involvement of the CCR5 59029 A/G polymorphism. PLoS One. 2015;10(11):e0141847.
   Web of Science ®Google Scholar
• Oliveira AP, Bernardo CR, Camargo AV, et al. CCR5 chemokine receptor gene variants in chronic Chagas’ disease. Int J Cardiol. 2014;176(2):520–522.
   PubMed Web of Science ®Google Scholar
• Florez O, Martin J, Gonzalez CI. Genetic variants in the chemokines and chemokine receptors in Chagas disease. Hum Immunol. 2012;73(8):852–858.
   PubMed Web of Science ®Google Scholar
• Campbell DA, Westenberger SJ, Sturm NR. The determinants of Chagas disease: connecting parasite and host genetics. Curr Mol Med. 2004;4(6):549–562.
   PubMed Web of Science ®Google Scholar
• Houston-Ludlam GA, Belew AT, El-Sayed NM. Comparative transcriptome profiling of human foreskin fibroblasts infected with the Sylvio and Y strains of Trypanosoma cruzi. PLoS One. 2016;11(8):e0159197.
   PubMed Web of Science ®Google Scholar
• Fernandez-Villegas A, Thomas MC, Carrilero B, et al. The innate immune response status correlates with a divergent clinical course in congenital Chagas disease of twins born in a non-endemic country. Acta Trop. 2014;140:84–90.
   PubMed Web of Science ®Google Scholar
• Rizzo LV, Cunha-Neto E, Teixeira AR. Autoimmunity in Chagas’ disease: immunomodulation of autoimmune and T. cruzi-specific immune responses. Mem Inst Oswaldo Cruz. 1988;83 Suppl 1:360–362.
   PubMedGoogle Scholar
• Leon Rodriguez DA, Echeverria LE, Gonzalez CI, et al. Investigation of the role of IL17A gene variants in Chagas disease. Genes Immun. 2015;16(8):536–540.
   PubMed Web of Science ®Google Scholar
• Bellini MF, Silistino-Souza R, Varella-Garcia M, et al. Biologic and genetics aspects of chagas disease at endemic areas. J Trop Med. 2012;357948:2012.
   Google Scholar
• Nogueira LG, Frade AF, Ianni BM, et al. Functional IL18 polymorphism and susceptibility to Chronic Chagas Disease. Cytokine. 2015;73(1):79–83.
   PubMed Web of Science ®Google Scholar
• Vallejo A, Monge-Maillo B, Gutierrez C, et al. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. Acta Trop. 2016;164:117–124.
   PubMed Web of Science ®Google Scholar
• Fabbro DL, Olivera V, Bizai ML, et al. Humoral immune response against P2beta from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage. Am J Trop Med Hyg. 2011;84(4):575–580.
   PubMed Web of Science ®Google Scholar
• Vasconcelos RH, Montenegro SM, Azevedo EA, et al. Genetic susceptibility to chronic Chagas disease: an overview of single nucleotide polymorphisms of cytokine genes. Cytokine. 2012;59(2):203–208.
   PubMed Web of Science ®Google Scholar